Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2021 - 2025)

Kiniksa Pharmaceuticals International's Operating Leases history spans 5 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 17.2% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, down 17.2%, while the annual FY2025 figure was $6.5 million, 17.2% down from the prior year.
  • Operating Leases reached $6.5 million in Q4 2025 per KNSA's latest filing, down from $7.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $11.3 million in Q2 2023 to a low of $1.3 million in Q2 2022.
  • Average Operating Leases over 5 years is $6.1 million, with a median of $6.8 million recorded in 2025.
  • Peak YoY movement for Operating Leases: plummeted 63.49% in 2022, then skyrocketed 782.86% in 2023.
  • A 5-year view of Operating Leases shows it stood at $2.7 million in 2021, then dropped by 1.91% to $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then decreased by 21.42% to $7.9 million in 2024, then fell by 17.2% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Operating Leases are $6.5 million (Q4 2025), $7.0 million (Q3 2025), and $7.2 million (Q2 2025).